[go: up one dir, main page]

WO2011098799A3 - Traitement de maladie respiratoire - Google Patents

Traitement de maladie respiratoire Download PDF

Info

Publication number
WO2011098799A3
WO2011098799A3 PCT/GB2011/050224 GB2011050224W WO2011098799A3 WO 2011098799 A3 WO2011098799 A3 WO 2011098799A3 GB 2011050224 W GB2011050224 W GB 2011050224W WO 2011098799 A3 WO2011098799 A3 WO 2011098799A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
ethoxy
benzyl
hydroxy
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2011/050224
Other languages
English (en)
Other versions
WO2011098799A2 (fr
Inventor
Harry Finch
Craig Fox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmagen Therapeutics Inflammation Ltd
Original Assignee
Pulmagen Therapeutics Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmagen Therapeutics Inflammation Ltd filed Critical Pulmagen Therapeutics Inflammation Ltd
Publication of WO2011098799A2 publication Critical patent/WO2011098799A2/fr
Anticipated expiration legal-status Critical
Publication of WO2011098799A3 publication Critical patent/WO2011098799A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique contenant le composé 5-{4-[2-(5-éthyl-pyridin-2-yl)-2-hydroxy-éthoxy]-benzyl}-thiazolidine-2,4-dιone ou un sel pharmaceutiquement acceptable de ce dernier ainsi qu'un ou plusieurs véhicules et/ou excipients. La composition est caractérisée en ce qu'au moins 95% en poids de la teneur en 5-{4-[2-(5-éthyl-pyridin-2-yl)-2- hydroxy-éthoxy]-benzyl}-thiazolidine-2,4-dione de la composition est la forme diastéréomère 5(R)-{4-[2-(5-éthyl-pyridin-2-yI)=2(S)-hydroxy-éthoxy]=benzyl}- thiazolidιne-2,4-dione et en ce que moins de 5% en poids est constitué d'une ou plusieurs des trois formes diastéréomères.
PCT/GB2011/050224 2010-02-10 2011-02-09 Traitement de maladie respiratoire Ceased WO2011098799A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1002224.2 2010-02-10
GBGB1002224.2A GB201002224D0 (en) 2010-02-10 2010-02-10 Respiratory disease treatment

Publications (2)

Publication Number Publication Date
WO2011098799A2 WO2011098799A2 (fr) 2011-08-18
WO2011098799A3 true WO2011098799A3 (fr) 2015-09-11

Family

ID=42110492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/050224 Ceased WO2011098799A2 (fr) 2010-02-10 2011-02-09 Traitement de maladie respiratoire

Country Status (2)

Country Link
GB (1) GB201002224D0 (fr)
WO (1) WO2011098799A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
AU2014236510A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US20170368150A1 (en) * 2014-09-08 2017-12-28 Gotham Biopharmaceuticals, Inc. Methods of treating pulmonary sarcoidosis
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109088A2 (fr) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Therapies d'association d'analogues de la thiazolidinedione
WO2010015818A1 (fr) * 2008-08-07 2010-02-11 Argenta Discovery Limited Traitement de maladie respiratoire
WO2010150014A1 (fr) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
WO1993018007A1 (fr) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
WO2000021143A1 (fr) 1998-10-05 2000-04-13 Osram Opto Semiconductors Gmbh & Co. Ohg Puce semi-conductrice emettant des rayonnements
SI20116A (sl) 1998-12-02 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov postopek za pripravo simvastatina in njegovih analogov
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
AU5629301A (en) 2000-04-27 2001-11-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments
DE10346940B3 (de) 2003-10-06 2005-06-16 Schering Ag Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
WO2002012265A1 (fr) 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYLE) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYLE-3-OXO-ANDROST-1,4,-DIENE-17-ACIDE CARBOTHIOIQUE S-FLUOROMETHYLE ESTER UTILISE COMME AGENT ANTI INFLAMMATOIRE
AU2001288271A1 (en) 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
JP2005500290A (ja) 2001-06-12 2005-01-06 グラクソ　グループ　リミテッド 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
ATE417606T1 (de) 2001-09-14 2009-01-15 Glaxo Group Ltd Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
WO2003042229A1 (fr) 2001-11-12 2003-05-22 Glaxo Group Limited Esters heterocycliques non aromatiques de furan-2-one esters de 17 $g(b) carboxyl ou 17 $g(b) carbothio glucocorticoides
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
WO2003048181A1 (fr) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha.-esters cycliques de 16-methylpregnan-3,20-dione en tant qu'agents anti-inflammatoires
WO2003062259A2 (fr) 2002-01-21 2003-07-31 Glaxo Group Limited Nouveaux composes
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
JP2005523920A (ja) 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
WO2003099764A1 (fr) 2002-05-28 2003-12-04 Theravance, Inc. Agonistes du recepteur adrenergique $g(b)2 alcoxy aryle
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1440966A1 (fr) 2003-01-10 2004-07-28 Pfizer Limited Dérivés d'indole utilisables pour traiter des maladies
CA2499314C (fr) 2002-10-11 2010-08-24 Pfizer Inc. Derives d'indole utilises comme agonistes beta-2
ES2291733T3 (es) 2002-10-22 2008-03-01 Glaxo Group Limited Compuestos de ariletanolamina medicinales.
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
DK1556342T3 (da) 2002-10-28 2008-07-21 Glaxo Group Ltd Phenethanolaminderivat til behandling af respiratoriske sygdomme
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10258695A1 (de) 2002-12-16 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neuer, langwirksamer Beta-agonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
EP1460064A1 (fr) 2003-03-14 2004-09-22 Pfizer Limited Derivés de Indole-2-carboxamide comme beta-2 agonistes
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
EP1613315B1 (fr) 2003-04-04 2009-01-21 Novartis AG Derives de quinoline-2-one permettant de traiter des maladies des voies respiratoires
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
EP1477167A1 (fr) 2003-05-15 2004-11-17 Pfizer Limited Dérivés de [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl come agonistes de beta2
ES2329133T3 (es) 2003-05-28 2009-11-23 Theravance, Inc. Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos.
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
ATE384697T1 (de) 2003-06-04 2008-02-15 Pfizer 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
CA2531060A1 (fr) 2003-07-01 2005-01-13 Schering Aktiengesellschaft Derives de pentanol substitues par un heterocycle, procede de production de ces composes et leur utilisation comme agents anti-inflammatoires
WO2005033121A2 (fr) 2003-10-03 2005-04-14 King Pharmaceuticals Research & Development, Inc. Synthese de 2-aralkyloxyadenosines, 2-alkoxyadenosines, et leurs analogues
DE10347385A1 (de) 2003-10-08 2005-05-12 Schering Ag Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DK1670458T3 (da) 2003-10-08 2007-04-23 Bayer Schering Pharma Ag 1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
GB0323701D0 (en) 2003-10-09 2003-11-12 Glaxo Group Ltd Formulations
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
US8506794B2 (en) 2003-12-19 2013-08-13 Shell Oil Company Systems, methods, and catalysts for producing a crude product
DE102004001413A1 (de) 2004-01-09 2005-08-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
ES2289691T3 (es) 2004-01-22 2008-02-01 Pfizer, Inc. Derivados de sulfonamida para el tratamiento de enfermedades.
OA13362A (en) 2004-01-22 2007-04-13 Pfizer Sulfonamide derivatives for the treatment of diseases.
DE102004003428A1 (de) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
WO2005077361A1 (fr) 2004-02-14 2005-08-25 Boehringer Ingelheim International Gmbh Nouveaux beta-2-agonistes a action longue duree et leur utilisation comme medicaments
WO2005092861A1 (fr) 2004-03-11 2005-10-06 Pfizer Limited Derives de quinolinone compositions pharmaceutiques contenant ces derives et utilisation de celles-ci
EP1577306A1 (fr) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG nouveaux dérivés de Benzoxazinone comme béta-mimétiques de longue durée et leur utilisation pour le traitement des maladies des voies respiratoires
EP1577292A1 (fr) 2004-03-17 2005-09-21 Pfizer Limited Dérivées de phenylaminoethanol comme agonistes des recepteurs beta2
HN2004000023A (es) 2004-03-22 2007-11-23 Mars Inc Mascadura para animales
WO2005092860A1 (fr) 2004-03-23 2005-10-06 Pfizer Limited Composes servant au traitement de maladies
PL1730103T3 (pl) 2004-03-23 2010-10-29 Pfizer Pochodne formamidu użyteczne jako adrenoreceptor
JP4108117B2 (ja) 2004-03-23 2008-06-25 ファイザー・インク 疾患を処置するための化合物
WO2005092841A1 (fr) 2004-03-23 2005-10-06 Pfizer Limited Composes presentant une activite beta-agoniste
CA2565243A1 (fr) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires
EP1595873A1 (fr) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Dérivés de cycloalkyle pour le traitement des maladies respiratoires
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024451A1 (de) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
WO2005121065A2 (fr) 2004-06-03 2005-12-22 Theravance, Inc. Agonistes des recepteurs $g(b)2-adrenergiques diaminiques
JP2008507532A (ja) 2004-07-21 2008-03-13 セラヴァンス， インコーポレーテッド ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト
WO2006016245A1 (fr) 2004-08-05 2006-02-16 Ranbaxy Laboratories Limited Antagonistes des récepteurs muscariniques
US7566785B2 (en) 2004-09-10 2009-07-28 Theravance, Inc. Amidine substituted aryl aniline compounds
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
WO2006051373A1 (fr) 2004-11-12 2006-05-18 Pfizer Limited Composes permettant de traiter de maladies
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
TW200745099A (en) 2006-03-02 2007-12-16 Sankyo Co Optically active thiazolidinedione derivatives
EP2001468B1 (fr) 2006-03-16 2012-10-31 Metabolic Solutions Development Company LLC Analogues de la thiazolidinedione
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109088A2 (fr) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Therapies d'association d'analogues de la thiazolidinedione
WO2010015818A1 (fr) * 2008-08-07 2010-02-11 Argenta Discovery Limited Traitement de maladie respiratoire
WO2010150014A1 (fr) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JAMALI B ET AL: "Investigation of racemisation of the enantiomers of glitazone drug compounds at different pH using chiral HPLC and chiral CE", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, NEW YORK, NY, US, vol. 46, no. 1, 7 January 2008 (2008-01-07), pages 82 - 87, XP002587887, ISSN: 0731-7085, [retrieved on 20070910], DOI: DOI:10.1016/J.JPBA.2007.09.004 *
NARALA VENKATA R ET AL: "Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma", RESPIRATORY RESEARCH, BIOMED CENTRAL LTD., LONDON, GB, vol. 8, no. 1, 4 December 2007 (2007-12-04), pages 90, XP021031353, ISSN: 1465-9921 *
PARKS D J ET AL: "Differential activity of rosiglitazone enantiomers at PPARgamma", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 8, no. 24, 15 December 1998 (1998-12-15), pages 3657 - 3658, XP004819411, ISSN: 0960-894X, DOI: DOI:10.1016/S0960-894X(98)00664-7 *
TANIS S P ET AL: "Synthesis and biological activity of metabolites of the antidiabetic antihyperglycemic agent Pioglitazone", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39, no. 26, 1 January 1996 (1996-01-01), pages 5053 - 5063, XP002336054, ISSN: 0022-2623, DOI: DOI:10.1021/JM9605694 *

Also Published As

Publication number Publication date
WO2011098799A2 (fr) 2011-08-18
GB201002224D0 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
GB2465897A (en) Respiratory disease treatment
WO2011098799A3 (fr) Traitement de maladie respiratoire
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
WO2010068810A3 (fr) Amides substitués, et leurs procédés de production et d'utilisation
WO2009010416A3 (fr) Inhibiteurs de 11b-hydroxystéroïde déshydrogenase
NZ594332A (en) Compounds for the prevention and treatment of cardiovascular disease
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
WO2012032360A3 (fr) Nouvelle utilisation de composés biologiquement actifs
NZ582089A (en) Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
WO2007060140A3 (fr) Inhibiteurs de diacylglycérol acyltransférase (dgat)
IL205974A (en) 2- (5-Bromo-4- (4-Cyclopropylphenaphthalene-1-ram) -4 h-4,2,1- Triazole-3-Ilthio) Acetic acid or salt is acceptable in its pharmacy for use as a drug and a pharmaceutical preparation containing this compound
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
WO2008137779A3 (fr) Inhibiteurs macrocycliques innovants de la réplication du virus de l'hépatite c
EP2141155A4 (fr) Agent prophylactique et/ou thérapeutique contre l'hyperlipémie
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
WO2012001074A3 (fr) Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté
EP3276004A3 (fr) Procédés de traitement d'une maladie rénale chronique
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them
EP1774968A4 (fr) Dérivé de benzylisoquinoléine - ou dérivé bisbenzylisoquinoléine - contenant un agent psychotrope, analgésique et/ou antiphlogistique, et aliment de santé.
WO2008039406A3 (fr) Formulations lyophilisées à délitement rapide d'un antagoniste du récepteur de la thrombine
JP2011046708A5 (fr)
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11703726

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11703726

Country of ref document: EP

Kind code of ref document: A2